Christopher Cecchini
Optometrist · Pittsburgh, PANPI 1013907997
Payments from drug & device makers
Across 284 payments — averaging $23.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$1K
- Bausch & Lomb Americas Inc.$801
- Shire North American Group Inc$775
- Sun Pharmaceutical Industries Inc.$530
- Coopervision Inc.$525
- plus $2K from 14 others
What the payments were for
- Consulting fees$1,54023%
- Travel & lodging$80%
- Food & beverage$5,03676%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $1,239 |
| Novartis | 78 | $1,155 |
| Bausch & Lomb Americas Inc. | 49 | $801 |
| Shire North American Group Inc | 6 | $775 |
| Sun Pharmaceutical Industries Inc. | 30 | $530 |
| Coopervision Inc. | 3 | $525 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 31 | $511 |
| Tarsus Pharmaceuticals, Inc. | 13 | $368 |
| Oyster Point Pharma, Inc. | 15 | $294 |
| Biotissue Holdings Inc. | 4 | $85 |
| Amgen(2 entities) | 3 | $62 |
| Genentech USA, Inc. | 1 | $46 |
| Kala Pharmaceuticals, Inc. | 2 | $45 |
| Dompe US, Inc. | 1 | $34 |
| Eyevance Pharmaceuticals LLC | 2 | $26 |
| NEW World Medical,inc. | 2 | $22 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $20 |
| Johnson & Johnson Vision Care, Inc. | 1 | $19 |
| Alcon | 1 | $15 |
| Aerie Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$690
- VUITY$617
- Clariti Contact Lens$500
- RESTASIS$130
- BIOTRUE ONE DAY$125
How this compares
$6,583 in reported general payments places this provider in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 90 | $127,744 |
| RestasisCyclosporine | 87 | $94,699 |
| Cyclosporine | 106 | $60,197 |
| XdemvyLotilaner | 29 | $52,256 |
| LumiganBimatoprost | 80 | $35,815 |
| RocklatanNetarsudil Mesylat/Latanoprost | 60 | $34,992 |
| CequaCyclosporine | 36 | $29,224 |
| VyzultaLatanoprostene Bunod | 39 | $14,178 |
| CombiganBrimonidine Tartrate/Timolol | 25 | $13,369 |
| MieboPerfluorohexyloctane/Pf | 13 | $12,314 |
| TyrvayaVarenicline Tartrate | 16 | $9,886 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 28 | $6,028 |
| RhopressaNetarsudil Mesylate | 11 | $4,450 |
| Fluorometholone | 34 | $4,294 |
| Prednisolone Acetate | 97 | $4,063 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $801 | $154,236142 claims |
| AbbVieRestasis, Lumigan, Combigan | $1,239 | $143,882192 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $368 | $52,25629 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $12 | $39,44271 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $530 | $29,22436 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $294 | $9,88616 claims |
| AlconSimbrinza | $15 | $3,48616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Other optometrist in Pittsburgh
- Erick HendersonPittsburgh$266K
- William Vincett JrPittsburgh$57K
- Joshua ClermontPittsburgh$24K
- Jane ManlyPittsburgh$13K
- Mark ClementPittsburgh$11K
- James DeomHazle Township$793K
- Gregory CaldwellDuncansville$547K
- Glenn CorbinWyomissing$426K
- Leslie O DellNew Freedom$409K
- Kevin BistlinePlymouth Meeting$302K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.